

**SUPPLEMENTARY TABLE 2. Serum anti-spike and anti-receptor binding domain immunoglobulin G levels\* after full vaccination among hospitalized veterans without current or prior SARS-CoV-2 infection<sup>†</sup> by age, product, and days since vaccination — Five Veterans Affairs Medical Centers, United States, February 1–September 30, 2021<sup>§</sup>**

Characteristic	Total No. (%)	anti-spike IgG		anti-RBD IgG	
		Antibody concentration (BAU/mL) median [IQR]	p-value <sup>¶</sup>	Antibody concentration (BAU/mL) median [IQR]	p-value <sup>¶</sup>
<b>Age, yrs</b>					
18–49	8 (3.4)	460 [119–626]	Referent	630 [155–1003]	Referent
50–64	45 (19.2)	306 [153–808]	0.97	477 [217–1057]	0.89
65–74	91 (38.9)	193 [58–795]	0.71	310 [52–1264]	0.75
≥75	90 (38.5)	160 [35–564]	0.37	245 [36–713]	0.43
<b>COVID-19 vaccine product received (among fully vaccinated)</b>					
Pfizer-BioNTech	144 (61.5)	114 [31–345]	<0.01	124 [31–489]	<0.01
Moderna	90 (38.5)	580 [249–1412]		787 [346–1939]	
<b>No. of days since vaccination**</b>					
14–89	114 (48.7)	509 [125–1255]	Referent	672 [144–1747]	Referent
90–119	39 (16.7)	218 [58–407]	0.01	314 [47–572]	0.01
≥120	81 (34.6)	96 [36–262]	<0.01	111 [35–372]	<0.01

**Abbreviations:** BAU = binding antibody units; IgG = immunoglobulin G; RBD = receptor binding domain.

\* Anti-spike and anti-RBD IgG levels were measured in sera of hospitalized veterans collected at or within two days of hospital admission.

<sup>†</sup> Excluded 25 controls with anti-nucleocapsid antibodies (>11.8 BAU/mL), suggesting a prior SARS-CoV-2 infection.

<sup>§</sup> Serum specimens collected during March 22–August 31, 2021.

<sup>¶</sup> Testing for statistical significance was conducted using the Wilcoxon rank-sum test. Statistical significance was set at p < 0.05.

\*\* Interval from receipt of second COVID-19 mRNA vaccine dose to serum collection.